TIA
MCID: TRN015
MIFTS: 63

Transient Cerebral Ischemia (TIA)

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Transient Cerebral Ischemia

MalaCards integrated aliases for Transient Cerebral Ischemia:

Name: Transient Cerebral Ischemia 12 54 15 71
Transient Ischemic Attack 12 53 54 6 42 17 71
Transient Ischemic Attacks 12 15
Tia - Transient Ischaemic Attack 12
Transient Cerebral Ischaemia 12
Ischemic Attack, Transient 43
Tia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:224
MeSH 43 D002546
NCIt 49 C50781
SNOMED-CT 67 266257000
ICD10 32 G45.9
UMLS 71 C0007787 C0917805

Summaries for Transient Cerebral Ischemia

MedlinePlus : 42 A transient ischemic attack (TIA) is a stroke that lasts only a few minutes. It happens when the blood supply to part of the brain is briefly blocked. Symptoms of a TIA are like other stroke symptoms, but do not last as long. They happen suddenly, and include Numbness or weakness, especially on one side of the body Confusion or trouble speaking or understanding speech Trouble seeing in one or both eyes Difficulty walking Dizziness Loss of balance or coordination Most symptoms of a TIA disappear within an hour, although they may last for up to 24 hours. Because you cannot tell if these symptoms are from a TIA or a stroke, you should go to the hospital right away. TIAs are often a warning sign for future strokes. Taking medicine, such as blood thinners, may reduce your risk of a stroke. Your doctor might also recommend surgery. You can also help lower your risk by having a healthy lifestyle. This includes not smoking, not drinking too much, eating a healthy diet, and exercising. It is also important to control other health problems, such as high blood pressure and cholesterol. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Transient Cerebral Ischemia, also known as transient ischemic attack, is related to ischemia and amnestic disorder, and has symptoms including seizures, edema and tremor. An important gene associated with Transient Cerebral Ischemia is NOTCH3 (Notch Receptor 3), and among its related pathways/superpathways are Neuroscience and G-protein signaling Ras family GTPases in kinase cascades (scheme). The drugs Aspirin and Irbesartan have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A brain ischemia that is characterized by ischemia of brief duration and without resultant tissue death.

NINDS : 53 A transient ischemic attack (TIA) is a transient stroke that lasts only a few minutes. It occurs when the blood supply to part of the brain is briefly interrupted. TIA symptoms, which usually occur suddenly, are similar to those of stroke but do not last as long. Most symptoms of a TIA disappear within an hour, although they may persist for up to 24 hours. Symptoms can include: numbness or weakness in the face, arm, or leg, especially on one side of the body; confusion or difficulty in talking or understanding speech; trouble seeing in one or both eyes; and difficulty with walking, dizziness, or loss of balance and coordination.

Wikipedia : 74 A transient ischemic attack (TIA), commonly known as a mini-stroke, is a brief episode of neurological... more...

Related Diseases for Transient Cerebral Ischemia

Diseases related to Transient Cerebral Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 503)
# Related Disease Score Top Affiliating Genes
1 ischemia 31.7 MAP2 HSPA4 HSPA1A CASP3
2 amnestic disorder 31.0 MAPT DRD1 ACHE
3 retinal ischemia 30.8 IL1B HSPA4 CASP3
4 peripheral nervous system disease 30.7 IL1B CCL2 CASP3 ACHE
5 cytomegalovirus infection 30.6 IL1B CCL2 CASP3
6 carotid artery occlusion 30.3 MAP2 IL1B HSPA1A CASP3 APOH
7 anxiety 30.2 SLC1A1 IL1B GRIN2A ACHE
8 binswanger's disease 30.1 NOTCH3 MAPT ACHE
9 agraphia 29.9 MAPT ACHE
10 dementia 29.7 NOTCH3 MAPT MAP2 IL1B ACHE
11 encephalomalacia 29.7 MTHFR IL1B CASP3
12 spinal cord infarction 29.5 MTHFR APOH
13 retinal artery occlusion 29.4 MTHFR CCL2 APOH
14 homocysteinemia 29.4 MTHFR CCL2 APOH
15 vascular disease 29.3 MTHFR HSPA4 CCL2 CASP3 APOH
16 intracranial hypertension 29.3 MTHFR IL1B APOH
17 retinal vein occlusion 29.3 MTHFR IL1B CCL2 APOH
18 placenta disease 29.2 MTHFR IL1B APOH
19 migraine with or without aura 1 29.0 NOTCH3 MTHFR IL1B DRD1 APOH
20 migraine without aura 29.0 NOTCH3 MTHFR DRD1 CCR2 CCL2
21 vascular dementia 28.9 NOTCH3 MTHFR MAPT IL1B GRIN2A CASP3
22 cerebrovascular disease 28.9 NOTCH3 MTHFR MAPT APOH ACHE
23 thrombocytopenia 28.7 MTHFR IL1B CCL2 CASP3 APOH
24 myocardial infarction 28.6 MTHFR IL1B HSPA4 CCR2 CCL2 CASP3
25 stroke, ischemic 27.9 NOTCH3 MTHFR MAPT MAP2 IL1B HSPA4
26 mini stroke 11.9
27 paresthesia 11.7
28 pulmonary arteriovenous fistulas 11.7
29 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 11.7
30 essential thrombocythemia 11.7
31 moyamoya disease 1 11.7
32 carotid artery disease 11.7
33 sneddon syndrome 11.5
34 moyamoya disease 2 11.5
35 moyamoya disease 6 with or without achalasia 11.5
36 buerger disease 11.4
37 telangiectasia, hereditary hemorrhagic, type 4 11.4
38 moyamoya disease 5 11.4
39 aganglionosis, total intestinal 11.3
40 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 11.2
41 cerebral artery occlusion 10.8
42 palladium allergic contact dermatitis 10.6 IL1B CCL2
43 carbuncle 10.5 IL1B CASP3 ACHE
44 ectodermal dysplasia 1, hypohidrotic, x-linked 10.5 IL1B CCL2 CASP3
45 simultanagnosia 10.5 MAPT ACHE
46 congenital cytomegalovirus 10.5 IL1B CCL2
47 yellow fever 10.5 IL1B CCL2 CASP3
48 atrial fibrillation 10.5
49 pneumoconiosis 10.5 IL1B CCL2 CASP3
50 ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, autosomal recessive 10.4 IL1B CCL2 CASP3

Comorbidity relations with Transient Cerebral Ischemia via Phenotypic Disease Network (PDN): (show top 50) (show all 86)


Active Peptic Ulcer Disease Acute Cystitis
Acute Myocardial Infarction Alzheimer Disease
Anxiety Aortic Atherosclerosis
Aortic Valve Disease 1 Atrioventricular Block
Basilar Artery Insufficiency Benign Essential Hypertension
Bronchitis Bronchopneumonia
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Maxillary Sinusitis
Communicating Hydrocephalus Conjunctivitis
Conversion Disorder Cystitis
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Dysthymic Disorder
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Facial Paralysis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Heart Disease Hyperlipoproteinemia, Type Iv
Hypertension, Essential Hypertensive Encephalopathy
Hypoglycemia Hypoglycemic Coma
Hypothyroidism Inner Ear Disease
Intermediate Coronary Syndrome Intracranial Embolism
Intracranial Thrombosis Iron Deficiency Anemia
Kidney Disease Labyrinthitis
Left Bundle Branch Hemiblock Macular Degeneration, Age-Related, 1
Major Depressive Disorder Malignant Essential Hypertension

Graphical network of the top 20 diseases related to Transient Cerebral Ischemia:



Diseases related to Transient Cerebral Ischemia

Symptoms & Phenotypes for Transient Cerebral Ischemia

UMLS symptoms related to Transient Cerebral Ischemia:


seizures, edema, tremor, chest pain, back pain, angina pectoris, headache, syncope, amaurosis fugax, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness, transient ischemic attacks, differing symptoms, transient ischemic attacks, stereotypic symptoms

MGI Mouse Phenotypes related to Transient Cerebral Ischemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.93 ACHE CASP3 CCR2 DRD1 GRIN2A HSPA4
2 homeostasis/metabolism MP:0005376 9.77 ACHE APOH CASP3 CCR2 DRD1 IL1B
3 nervous system MP:0003631 9.4 ACHE CASP3 CCR2 DRD1 GRIN2A HSPA4

Drugs & Therapeutics for Transient Cerebral Ischemia

Drugs for Transient Cerebral Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 315)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
5
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
6
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
7
Sodium citrate Approved, Investigational Phase 4 68-04-2
8
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
9
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
10
Nicotine Approved Phase 4 54-11-5 942 89594
11
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
12
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
13
Metformin Approved Phase 4 657-24-9 14219 4091
14
Amlodipine Approved Phase 4 88150-42-9 2162
15
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
16
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
17
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
18
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
19
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
20
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
21
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
22
Simvastatin Approved Phase 4 79902-63-9 54454
23
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
24
Losartan Approved Phase 4 114798-26-4 3961
25
Pravastatin Approved Phase 4 81093-37-0 54687
26
Apixaban Approved Phase 4 503612-47-3 10182969
27
Atorvastatin Approved Phase 4 134523-00-5 60823
28
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
29
Lisinopril Approved, Investigational Phase 4 76547-98-3, 83915-83-7 5362119
30
Ethanol Approved Phase 4 64-17-5 702
31
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
32
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
33
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
34
Candesartan Experimental Phase 4 139481-59-7 2541
35
Dabigatran Investigational Phase 4 211914-51-1
36 Fibrinolytic Agents Phase 4
37 Analgesics, Non-Narcotic Phase 4
38 Analgesics Phase 4
39 Platelet Aggregation Inhibitors Phase 4
40 Cyclooxygenase Inhibitors Phase 4
41 Antirheumatic Agents Phase 4
42 Antipyretics Phase 4
43 Anti-Inflammatory Agents, Non-Steroidal Phase 4
44 Radiation-Protective Agents Phase 4
45 Phosphodiesterase 5 Inhibitors Phase 4
46 Vardenafil Dihydrochloride Phase 4
47 Citrate Phase 4
48 Sildenafil Citrate Phase 4 171599-83-0
49 Trace Elements Phase 4
50 Vitamins Phase 4

Interventional clinical trials:

(show top 50) (show all 503)
# Name Status NCT ID Phase Drugs
1 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
2 The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack.10 vs 30 Days of Combination ASA and Clopidogrel Study Unknown status NCT02144831 Phase 4 anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
3 A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
4 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography Unknown status NCT02826200 Phase 4 Acenocoumarol
5 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
6 Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients (ALEVENT) Unknown status NCT01503671 Phase 4 Atorvastatin
7 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT00498680 Phase 4 Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil
8 Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma? Unknown status NCT01470040 Phase 4 discontinuation of aspirin therapy;continuation of aspirin therapy
9 CRYptogenic STroke And underLying AF Trial Completed NCT00924638 Phase 4
10 ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial Completed NCT00161070 Phase 4 anticoagulation;aspirin and dipyridamole;aspirin alone
11 A Double-Blind, Randomized, Placebo- Controlled Study Of Atorvastatin As Prevention Of Cerebrovascular Events In Patients With A Previous Transient Ischemic Attack (TIA) Or Stroke Completed NCT00147602 Phase 4 atorvastatin
12 Preventing Recurrent Vascular Events and Neurological Worsening Through Intensive Organized Case-Management (PREVENTION) Trial Completed NCT00931788 Phase 4 Antihypertensive agents and lipid lowering therapy
13 Efficacy and Cost-effectiveness of Cost-free Pharmacotherapy for Smoking Cessation for High-risk Smokers With Cerebrovascular Disease Completed NCT00962988 Phase 4 Cost-Free Pharmacotherapy Group
14 The Effect of Dipyridamole on the Pharmacokinetics of Metformin Completed NCT01613755 Phase 4 Metformin, dipyridamole;Metformin
15 The Impact of Intensive Rosuvastatin Therapy on Cerebral Hemodynamics in Patients With Atherosclerotic Intracranial Arterial Stenosis Evaluated by Computed Tomography Perfusion (CTP) Completed NCT02594800 Phase 4 Rosuvastatin
16 A Trial of Telmisartan Prevention of Cardiovascular Disease Completed NCT01075698 Phase 4 Non-ARB (standard therapy);ARB (Telmisartan)
17 Combination of OLMesartan and Calcium Channel Blocker or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study) Completed NCT00454662 Phase 4 olmesartan medoxomil / amlodipine or azelnidipine;olmesartan medoxomil / low dose thiazide type drug
18 A Controlled Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Treating Paroxysmal Atrial Fibrillation. The Ablation for Paroxysmal Atrial Fibrillation (APAF2) Trial Completed NCT00340314 Phase 4 Antiarrhythmic Drug Therapy
19 The Ischemia Management With Accupril Post Bypass Graft Via Inhibition of the coNverting Enzyme (IMAGINE) Trial Completed NCT00269243 Phase 4 Quinapril
20 Determining the Optimal Dose of Tranexamic Acid in Decreasing Blood Loss During Lower Extremity Total Joint Arthroplasty Completed NCT02584725 Phase 4 Tranexamic Acid
21 Post Marketing Surveillance Study for LDL Apheresis Using H.E.L.P. Therapy Completed NCT00916643 Phase 4
22 Efficacy of Different Perioperative Statin Regimens on the Protection Against Post Coronary Artery Bypass Grafting Major Adverse Cardio-cerebral Events Completed NCT02706860 Phase 4 Atorvastatin
23 Multiple Intervention and AUdit in Renal Diseases to Optimize Care: the MAURO Study. Completed NCT00566033 Phase 4
24 A Comparison of Isolating the Pulmonary Veins With the Cryoballoon Catheter Versus Radiofrequency Segmental Isolation:a Randomized Controlled Prospective Non-inferiority Trial Completed NCT00774566 Phase 4
25 Evaluation of Late Clinical Events After Drug-eluting Versus Bare-metal Stents in Patients at Risk: BAsel Stent Kosten Effektivitäts Trial - PROspective Validation Examination Part II (BASKET-PROVE II) Completed NCT01166685 Phase 4
26 Magnetic Resonance Characterization of Carotid Atherosclerotic Plaque in Vivo: Effect of High Density Lipoprotein Elevation on Plaque Morphology Completed NCT00307307 Phase 4 Niacin/simvastatin compared to simvastatin alone at 2 doses
27 Efficacy of Two Different Doses of Atorvastatin for Prevention of Periprocedural Ischemic Brain Damage in Chinese Patients Undergoing Carotid Artery Stenting (CAS) Recruiting NCT03079115 Phase 4 High-dose Atorvastatin;Conventional-dose Atorvastatin
28 Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD Recruiting NCT03417388 Phase 4 High dose potent statin;ACE-I (lisinopril) or ARB (losartan);Aspirin
29 European Society of Hypertension and Chinese Hypertension League Stroke in Hypertension Optimal Treatment Trial Recruiting NCT01563731 Phase 4 all approved antihypertensive drugs; all approved statins
30 Beta-blockeRs tO patieNts With CHronIc Obstructive puLmonary diseasE Recruiting NCT03566667 Phase 4 Metoprolol;Standard care
31 Influenza Vaccination After Myocardial Infarction (IAMI Trial): A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on National Angiography and Angioplasty Registries Active, not recruiting NCT02831608 Phase 4
32 The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF) Not yet recruiting NCT04437654 Phase 4 Anticoagulation group(Apixaban group)
33 Use of Rosuvastatin to Achieve Lipid Targets in African American Subjects With Cerebrovascular Disease Terminated NCT01975194 Phase 4 Rosuvastatin
34 Optimization of Pre-surgical Testing With an Intensive Multifactorial Intervention to MinimiZe Cardiovascular Events in Orthopedic Surgery Terminated NCT01837069 Phase 4 Metoprolol;Lisinopril;Atorvastatin
35 Accelerated Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging Terminated NCT02114697 Phase 4 Statin therapy
36 Dabigatran-related Effect on Progression of Atrial Fibrosis in Patients With Atrial Fibrillation Terminated NCT01546883 Phase 4 Dabigatran etexilate (Pradaxa)
37 Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis Patients: A Randomized Control Trial Withdrawn NCT00390247 Phase 4 thalidomide
38 A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex® Septal Closure System Versus Best Medical Therapy in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale Unknown status NCT00201461 Phase 2, Phase 3 Best medical therapy
39 A Randomized, Open-label, Active-Controlled and Blinded-Endpoint Trial Comparing the Antiplatelet Effects of Ticagrelor Plus Aspirin Versus Clopidogrel Plus Aspirin in Chinese Patients With High-risk Transient Ischemic Attack or Minor Stroke. Unknown status NCT02506140 Phase 2, Phase 3 Ticagrelor and Acetylsalicylic acid;Clopidogrel and Acetylsalicylic acid
40 Treatment of Edoxaban Versus Aspirin for Non-disabling Cerebrovascular Events: Rationale, Objectives, and Design Unknown status NCT02221102 Phase 2, Phase 3 Aspirin;edoxaban;placebo
41 Randomized,Double-blind Trial Comparing the Effects of a Rivaroxaban Regimen During the First 30 Days,Versus Aspirin for the Acute Treatment of TIA or Minor Stroke Unknown status NCT01923818 Phase 2, Phase 3 rivaroxaban;Aspirin;placebo
42 The Impact of Repeated Bilateral Limb Remote Ischemic Conditioning on Patients With Chronic Cerebral Ischemia: Establishment of Optimized Algorithm on the Basis of Feasibility, Safety and Efficacy Unknown status NCT03105141 Phase 2, Phase 3
43 A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular EMbolic Events During Transcatheter Aortic Valve Implantation (TAVI) OperationS - the PTOLEMAIOS Study. Unknown status NCT02989558 Phase 3 Ticagrelor plus ASA;Clopidogrel plus ASA
44 SAINT (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke Completed NCT00061022 Phase 3 NXY-059
45 Comprehensive Cardiac Rehabilitation Programming For Patients Following Transient Ischemic Attack Completed NCT00536562 Phase 3
46 Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease Completed NCT00984308 Phase 2, Phase 3
47 Carotid Artery Revascularization Using the Boston Scientific EPI Filter Wire EZ™ and the EndoTex™ NexStent™ Completed NCT00600327 Phase 3
48 Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery Completed NCT00235248 Phase 3 Warfarin;Clopidogrel-aspirin
49 Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation Completed NCT02283294 Phase 3 Apixaban;Warfarin
50 Endarterectomy Versus Angioplasty in Patients With Severe Symptomatic Carotid Stenosis Completed NCT00190398 Phase 3

Search NIH Clinical Center for Transient Cerebral Ischemia

Cochrane evidence based reviews: ischemic attack, transient

Genetic Tests for Transient Cerebral Ischemia

Anatomical Context for Transient Cerebral Ischemia

MalaCards organs/tissues related to Transient Cerebral Ischemia:

40
Brain, Heart, Testes, Eye, Endothelial, Kidney, Spinal Cord

Publications for Transient Cerebral Ischemia

Articles related to Transient Cerebral Ischemia:

(show top 50) (show all 9475)
# Title Authors PMID Year
1
Transient Ischemic Attack. 42 61
32402163 2020
2
Carotid plaque magnetic resonance imaging and recurrent stroke risk: A systematic review and meta-analysis. 61 42
32221065 2020
3
Study on the risk prediction for cerebral infarction after transient ischemic attack: A STROBE compliant study. 42 61
32176078 2020
4
Ischemia-related changes in naive and mutant forms of ubiquitin and neuroprotective effects of ubiquitin in the hippocampus following experimental transient ischemic damage. 61 54
19666022 2009
5
Cerebral ischemia/stroke and small ubiquitin-like modifier (SUMO) conjugation--a new target for therapeutic intervention? 61 54
18410505 2008
6
Postischemic alterations of BDNF, NGF, HSP 70 and ubiquitin immunoreactivity in the gerbil hippocampus: pharmacological approach. 54 61
16810563 2007
7
Transient cerebral ischemia induces delayed proapoptotic Bad translocation to mitochondria in CA1 sector of hippocampus. 61 54
15710244 2005
8
Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. 61 54
14764933 2004
9
Phospholipase A2, hydroxyl radicals, and lipid peroxidation in transient cerebral ischemia. 61 54
14580322 2003
10
Differential expression of HSC73 and HSP72 mRNA and proteins between young and adult gerbils after transient cerebral ischemia: relation to neuronal vulnerability. 61 54
10908039 2000
11
Leukocyte activation: relation to cardiovascular mortality after cerebrovascular ischemia. 54 61
10686447 2000
12
Immunoelectron microscopic study of c-Fos, c-Jun and heat shock protein after transient cerebral ischemia in gerbils. 61 54
9930891 1999
13
Increasing levels of leukocyte-derived inflammatory mediators in plasma and cAMP in platelets during follow-up after acute cerebral ischemia. 61 54
9774747 1998
14
677C to T mutation in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene and plasma homocyst(e)ine levels in patients with TIA or minor stroke. 61 54
9562260 1998
15
Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischemic cerebrovascular diseases. 54 61
8841320 1996
16
Disturbances of calcium homeostasis within the endoplasmic reticulum may contribute to the development of ischemic-cell damage. 54 61
8910877 1996
17
Induction of c-fos and c-jun gene products and heat shock protein after brief and prolonged cerebral ischemia in gerbils. 61 54
7660411 1995
18
Blockade of ornithine decarboxylase enzyme protects against ischemic brain damage. 54 61
7929646 1994
19
Coexpression of c-fos and hsp70 mRNAs in gerbil brain after ischemia: induction threshold, distribution and time course evaluated by in situ hybridization. 61 54
7854054 1994
20
An immunohistochemical study of parvalbumin containing interneurons in the gerbil hippocampus after cerebral ischemia. 61 54
7838065 1994
21
Delayed damage of striatal interneurons after cerebral ischemia in the gerbil. 61 54
7970228 1994
22
Hemostatic markers in acute transient ischemic attacks. 61 54
8303732 1994
23
[Induction of HSP70 and neuronal damage following transient cerebral ischemia in rats]. 61 54
8239864 1993
24
Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia. 54 61
8417138 1993
25
Autoradiographic analysis of dopamine D1 receptors in the gerbil brain following transient cerebral ischemia. 54 61
1487117 1992
26
Calcium/calmodulin dependent protein kinase II mRNA in the gerbil brain after cerebral ischemia. 54 61
1331917 1992
27
Activity of ornithine decarboxylase and S-adenosylmethionine decarboxylase in transient cerebral ischemia: relationship to the duration of vascular occlusion. 61 54
1499693 1992
28
Hyperglycemia suppresses c-fos mRNA expression following transient cerebral ischemia in gerbils. 61 54
1727138 1992
29
Postischemic alteration of muscarinic acetylcholine and adenosine A1 binding sites in gerbil brain. Protective effects of a novel vinca alkaloid derivative, vinconate, and pentobarbital using an autoradiographic study. 54 61
1529167 1992
30
Postischemic alteration of muscarinic acetylcholine, adenosine A1 and calcium antagonist binding sites in selectively vulnerable areas: an autoradiographic study of gerbil brain. 61 54
1666408 1991
31
Mild hypothermia ameliorates ubiquitin synthesis and prevents delayed neuronal death in the gerbil hippocampus. 61 54
1660190 1991
32
An immunohistochemical study of MAP2 and clathrin in gerbil hippocampus after cerebral ischemia. 61 54
1722131 1991
33
MiR-211 protects cerebral ischemia/reperfusion injury by inhibiting cell apoptosis. 61
32050841 2020
34
A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population. 61
32473496 2020
35
High ambient temperature in summer and risk of stroke or transient ischemic attack: A national study in Israel. 61
32474306 2020
36
Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation. 61
32359718 2020
37
Symptomatic arrhythmias after catheter ablation of atrioventricular nodal reentrant tachycardia (AVNRT): results from the German Ablation Registry. 61
31784903 2020
38
Inconsistent Classification of Mild Stroke and Implications on Health Services Delivery. 61
32001257 2020
39
Higher Long-Term Mortality with Carotid Artery Stenting in Asymptomatic Male Compared with Female Patients in the Southeastern Vascular Study Group. 61
32027990 2020
40
Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial. 61
32568642 2020
41
Factors associated with medication persistence among ischemic stroke patients: a systematic review. 61
32321382 2020
42
Stroke/Transient Ischemic Attack Among Patients With Acute Coronary Syndromes. 61
32000506 2020
43
Involuntary Hand-Shaking: Transient Ischemic Attack, Seizure, or Psychogenic? 61
32337744 2020
44
Transient Ischemic Attack in a Five-Year-Old Girl. 61
32084115 2020
45
Antithrombotic Therapy in Patients With Prior Stroke/Transient Ischemic Attack and Acute Coronary Syndromes. 61
32116009 2020
46
Can Carotid Endarterectomy be Performed Safely within 14 days after Intravenous Thrombolysis for Acute Stroke? 61
31918038 2020
47
Effectiveness of mono antiplatelet therapy vs dual antiplatelet therapy in ischemic stroke or transient ischemic attack-Special subgroup consideration for the African-American Population. 61
32243645 2020
48
Delays in Stroke Onset to Hospital Arrival Time During COVID-19. 61
32432998 2020
49
Acute Stroke in Times of the COVID-19 Pandemic: A Multicenter Study. 61
32516064 2020
50
Mild carotid stenosis creates gradual, progressive, lifelong brain, and eye damage: An experimental laboratory rat model. 61
31891180 2020

Variations for Transient Cerebral Ischemia

ClinVar genetic disease variations for Transient Cerebral Ischemia:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 NOTCH3 NM_000435.3(NOTCH3):c.457C>T (p.Arg153Cys)SNV Pathogenic 208501 rs797045014 19:15302993-15302993 19:15192182-15192182
2 NOTCH3 NM_000435.3(NOTCH3):c.1450T>G (p.Cys484Gly)SNV Likely pathogenic 523370 rs1555728965 19:15299088-15299088 19:15188277-15188277

Expression for Transient Cerebral Ischemia

Search GEO for disease gene expression data for Transient Cerebral Ischemia.

Pathways for Transient Cerebral Ischemia

GO Terms for Transient Cerebral Ischemia

Cellular components related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 10.18 PTK2B ODC1 NOTCH3 MTHFR MAPT MAP2
2 dendrite GO:0030425 9.73 SLC1A1 PTK2B MAPT MAP2 DRD1 CCR2
3 cell body GO:0044297 9.63 PTK2B MAPT MAP2
4 glial cell projection GO:0097386 9.49 SLC1A1 MAPT
5 nuclear periphery GO:0034399 9.48 MAPT MAP2
6 NMDA selective glutamate receptor complex GO:0017146 9.43 PTK2B GRIN2A
7 neuronal cell body GO:0043025 9.43 SLC1A1 PTK2B MAPT MAP2 CCR2 CASP3
8 main axon GO:0044304 9.4 MAPT MAP2
9 proximal dendrite GO:1990635 9.32 SLC1A1 MAP2
10 distal dendrite GO:0150002 9.16 SLC1A1 MAP2
11 dendritic spine GO:0043197 9.02 SLC1A1 PTK2B MAPT GRIN2A DRD1

Biological processes related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.91 IL1B CCR2 CCL2 CASP3
2 memory GO:0007613 9.75 MAPT GRIN2A DRD1
3 response to drug GO:0042493 9.72 PTK2B MTHFR GRIN2A DRD1 CASP3
4 response to wounding GO:0009611 9.7 GRIN2A CCR2 CASP3
5 chemokine-mediated signaling pathway GO:0070098 9.69 PTK2B CCR2 CCL2
6 cellular response to organic cyclic compound GO:0071407 9.67 IL1B CCL2 CASP3
7 sensory perception of pain GO:0019233 9.63 GRIN2A CCR2 CCL2
8 dopamine metabolic process GO:0042417 9.6 GRIN2A DRD1
9 NAD biosynthetic process GO:0009435 9.59 KYNU KMO
10 cellular homeostasis GO:0019725 9.58 CCR2 CCL2
11 regulation of synaptic plasticity GO:0048167 9.58 PTK2B MAPT GRIN2A
12 regulation of calcium-mediated signaling GO:0050848 9.57 PTK2B MAPT
13 regulation of microtubule polymerization GO:0031113 9.56 MAPT MAP2
14 pyridine nucleotide biosynthetic process GO:0019363 9.55 KYNU KMO
15 tryptophan catabolic process GO:0006569 9.54 KYNU KMO
16 long-term synaptic potentiation GO:0060291 9.54 PTK2B GRIN2A DRD1
17 positive regulation of NMDA glutamate receptor activity GO:1904783 9.48 CCR2 CCL2
18 'de novo' NAD biosynthetic process from tryptophan GO:0034354 9.43 KYNU KMO
19 cellular response to organic substance GO:0071310 9.43 MAP2 IL1B CASP3
20 anthranilate metabolic process GO:0043420 9.16 KYNU KMO
21 quinolinate biosynthetic process GO:0019805 8.96 KYNU KMO
22 positive regulation of synaptic transmission, glutamatergic GO:0051968 8.92 PTK2B DRD1 CCR2 CCL2

Molecular functions related to Transient Cerebral Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 NMDA glutamate receptor activity GO:0004972 8.96 PTK2B GRIN2A
2 CCR2 chemokine receptor binding GO:0031727 8.62 CCR2 CCL2

Sources for Transient Cerebral Ischemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....